Biotech beats the general market in the long run
Over the last couple of decades a large number of Biotech-companies have closed down, but the relatively few market winners have done so well that the Biopharma-index triumphs over the general market.
Despite the fact that investors are getting rid of biotech-shares as the general willingness to take risks is dropping off, the American Biotech-index has completely outperformed the general industry-index over a period of 17 years.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
He bites his tongue for no one
For abonnenter
